


# Gall Bladder Polyp to Carcinoma – “The Road to Hell”

Authors: Karthik Ganesan, Shivsamb Jalkote, Ankit Jain, Slesha Bhalja, Shah Alam, Swarup Nellore,  
Sir.H.N.Reliance Foundation Hospital and Research Center


Mumbai | India

Email: [karthik.s.ganesan@rfhospital.org](mailto:karthik.s.ganesan@rfhospital.org)  
[drkarthikg@gmail.com](mailto:drkarthikg@gmail.com)



The authors have no financial or other disclosures

Presenting Author  
Dr.Ankit Jain, MBBS, MD  
Sir.H.N.Reliance Foundation Hospital and Research  
Center  
Mumbai | India



# LEARNING OBJECTIVES


- Discuss etiopathogenesis of GB polyps and Cancer.
- Review the joint guidelines for management of GB polyp by ESGAR, EAES, EFISDS and ESGE.
- Discuss key imaging features and pathways of spread of GBC [Gall bladder carcinoma].
- Discuss imaging mimics of GBC.
- Review current guidelines for management of GBC.

# EPIDEMIOLOGY

- Gall bladder polyps are considered as elevation of the gallbladder mucosa that protrudes into the gallbladder lumen.
- Common incidentalomas with a reported prevalence of 0.3 – 9.5%.
- Majority of the gallbladder polyps are pseudopolyps [70%] and benign.
- True gall bladder polyps can be benign and malignant.



# Classification



- Due to pre-malignant potential of true polyp, and poor prognosis of gallbladder carcinoma, they need meticulous assessment and management.




- Need of early diagnosis*** - Gall bladder carcinoma carries poor prognosis.


5-year survival rate in Carcinoma gall bladder	
Stage I (confined to the muscularis mucosa)	100%
Stage II (confined to the perimuscular connective tissue)	57-72 %
Stage III (perforates serosa)	< 25%

ESGAR with collaboration of EAES, EFISDS & ESGE sought to develop evidence based consensus guidelines in order to address:

1. Which patients require cholecystectomy?
  2. Which patients require USG follow-up?
  3. What should be the frequency & duration of follow-up?
- European Society of Gastrointestinal and Abdominal Radiology (ESGAR) , European Association for Endoscopic Surgery (EAES) International Society of Digestive Surgery – European Federation (EFISDS) , European Society of Gastrointestinal Endoscopy (ESGE)







51 year old, Indian ethnicity male patient, with incidentally detected gall polyp of size 5mm.

PEARL – Polyp of <5mm, in an Indian patient requires follow-up.

GB Polyp on USG

< 5 mm

Does the pt. have symptoms ?

No


Risk factors for GB malignancy

- Age >50 yrs
- Primary sclerosing cholangitis
- Indian ethnicity
- Sessile polyp (focal wall thickening >4mm)

Yes

Polyp < 6mm :  
follow-up USG at  
6M/1/2/3/4/5 years





58 year old, Indian ethnicity male patient, with incidentally detected gall polyp of size 7 mm.

PEARL – Polyp of 6-9mm, in Indian patient, cholecystectomy is always preferred.

GB Polyp on USG

< 10 mm

Does the pt. have symptoms ?

No



Risk factors for GB malignancy

- Age >50 yrs
- Primary sclerosing cholangitis
- Indian ethnicity
- Sessile polyp (focal wall thickening > 4 mm)

Yes

Polyp 6-9 mm :  
cholecystectomy, if  
not then follow up






GB Polyp on USG

&gt; 10 mm

Cholecystectomy, if  
not then follow-up

50 year old, Indian ethnicity male patient, with incidental detected gall polyp of size 11mm.

PEARL – Polyp of 10mm or more, patient directly goes for cholecystectomy, irrespective of risk factors.






# Risk Factors for Gall bladder Malignancy

Age	Advancing age with 50 years as cut-off for intensive management plan.
Sex	Women > Men, especially in Asian females.
Ethnicity	~ 13 times higher risk in Indian compared to Caucasian population.
Morphology	Sessile polyp
Numbers	Single [frequently malignant], multiple [usually cholesterol polyp].
Primary sclerosing cholangitis	Increase the risk, mainly in polyp > 6mm
Tumor markers [Serum CEA and CA 19-9]	Little role in differentiating benign and malignancy.

Gall bladder carcinoma, although a rare illness, is the most common malignancy of the biliary tract, with traditionally poor outcome because of the following reasons:

- Often minimally symptomatic/ asymptomatic in its early stages.
- Metastasis and invasion often before diagnosis.
- Not sensitive to radiotherapy and chemotherapy.
- 5-year survival rate of less than 5% in advanced stage.

In early-stage disease, a 5-year survival rate of 75%-100% can be achieved



So, the primary goal in the management of gallbladder polyps is to prevent or early detection of the gallbladder carcinoma.

# Risk Factors for Gall bladder Malignancy

## Demographics

- Advancing age
- Female gender
- Obesity
- Geographical and ethnicity
- Genetic predisposition

## Pathologies

- Cholelithiasis
- Porcelain gallbladder
- Gallbladder polyps
- Congenital biliary cysts
- Ductal anomalies

## Exposure

- Heavy metals
- Medications: methyldopa, OCP, isoniazid, and estrogen
- Smoking.

## Infection

- Salmonella
- Helicobacter



# Mechanisms of Initiation of Cancer

Chronic inflammation



Recurrent or chronic inflammation results in detrimental damage of  
DNA



Tissue repeatedly attempts at restoration and provokes tissue  
proliferation



Release many cytokines and growth factors, and predispose cells to  
oncogenic transformation

# Principles of Imaging - GB polyps

Abdominal ultrasonography considered as the best modality for diagnosing gallbladder polyps, because of accessibility, low cost, with good sensitivity and specificity.

## ULTRASONOGRAPHY

- **Best Modality** for diagnosis
- Seen As An Elevation Of GB Wall That Protrudes Into The Lumen.
- Should Not Be Mobile Or Demonstrate Posterior Acoustic Shadow

## C.T.

- **Not sensitive** in detecting small gallbladder polyps.
- Larger polyps - soft tissue attenuation projections with similar enhancement as rest of the gallbladder.
- Increased enhancement raise suspicion of malignancy.


## M.R.I

- **Not routinely used** to evaluate gall bladder polyp.
- Seen as T2 hypointense foci with early enhancement and subsequent washout.
- DWI/ADC – differentiating benign and malignant polypoidal lesions by demonstrating high cellularity in later.

# Principles of Imaging - Carcinoma GB

- Cross sectional imaging plays a pivotal role in staging of the gall bladder cancer.
- CECT of abdomen and pelvis / CE-MRI with MRCP sequences with CT chest [contrast / noncontrast] should be performed.
- MRI - Better in evaluating masses within the gall bladder with bile duct involvement.
- Nodal disease should be properly evaluated, specifically the porta hepatis, left gastric and aorto-caval basin.
- PET/CT - limited sensitivity for disease perse. but has high specificity for regional nodal disease, so used in case of equivocal CT/MRI findings.
- Follow up imaging – includes CECT / MRI of abdomen and pelvis with chest imaging.





70-year-old Male with a 24mm polypoid lesion with multiple frond-like protuberances [yellow arrows] arising from the GB wall [hepatic  
H.P: Papillary Carcinoma of the Gall Bladder



# GB Cancer - Imaging techniques

## ULTRASONOGRAPHY

- Polypoidal / wall thickening / mass replacing the gall bladder.
- Malignant polyps are sessile, solitary, and >1cm and reveals internal vascularity.
- Easily detect invasion of liver parenchyma with loss of normal tissue interface.
- About 80% accurate in advanced stages

## C.T.

- Most common imaging modality for the detection of primary tumor and tumor staging.
- Precisely [85%] detect liver or porta hepatis invasion, lymphadenopathy, and the adjacent organs.
- Four patterns of gallbladder cancer on CT scan:
  1. Polypoid mass lesion(15– 25%)
  2. Focal wall thickening
  3. Diffuse wall thickening (20%)
  4. Mass replacing gallbladder (40–65%).

## M.R.I

- Superior to CT scan for differentiating T1a lesions from T1b or greater and also biliary involvement.
- Early and prolonged enhancement pattern of malignant lesions varies from the early enhancement with washout of benign masses.
- DWI/ADC – malignancy reveals high restricted diffusivity due to high cellularity and thus aids in differentiation the malignant from benign disease with high sensitivity.

## FDG – PET

- Problem solving modality.
- Helpful in diagnose the ambiguous primary lesions.
- Residual disease after cholecystectomy are better appreciated with this modality.
- Distant disease not otherwise appreciable by other imaging modalities.

# GB Cancer - Staging

Staging of gall bladder cancer.			
Stage I	T1 N0 M0	Confined to the inner layers	➡ Confined to GB
Stage II	IIA – T2a N0 M0	Invades the outer layers.	➡ Locally invasive
	IIB – T2b N0 M0		
Stage III	IIIA – T3 N0 M0	Invades the near by organs i.e. liver, small intestine, stomach or nodes.	➡ Locally advanced
	IIIB – T1-3 N1 M0		
Stage IV	IVA – T4 N0-1 M0	Involving multiple nearby organs or distant areas.	➡ Metastatic disease
	IVB – T1-4 N2 M0 or T1-4 N0-2 M1		



GB polyp Pathogenesis	GB polyp Guidelines	GB Ca. pathogenesis	GB Imaging	Mimics
<div data-bbox="0 187 659 900" data-label="Image"> </div>	<div data-bbox="659 187 1326 900" data-label="Image"> </div>	<div data-bbox="1326 187 1992 900" data-label="Image"> </div>	<div data-bbox="1992 187 2658 900" data-label="Image"> </div>	<div data-bbox="2658 187 3332 900" data-label="Image"> </div>
<div data-bbox="0 900 659 1800" data-label="Image"> </div>	<div data-bbox="659 900 1326 1800" data-label="Image"> </div>	<div data-bbox="1326 900 1992 1800" data-label="Image"> </div>	<div data-bbox="1992 900 2658 1800" data-label="Image"> </div>	<div data-bbox="2658 900 3332 1800" data-label="Image"> </div>

Focal Polypoidal subtype of Carcinoma Gall Bladder - Stage T2

Note, that contrast-enhanced CT and MRI perform similar in detection

Characterization and staging of T2 stage neoplasms. However, in early T1 stage neoplasms, MR performs better than CT



Polypoid / Papillary subtype of Carcinoma Gall Bladder - Note a large volume proliferative growth near completely occupying the gall bladder lumen with relative paucity of mural invasion

CT - Venous Phase









# Spread Patterns

- Locoregional spread *more common* than distant metastasis. Metastases usually occur in liver, lymph nodes, adjacent organs and peritoneum.
- Lymph nodal involvement - 60% of cases
- Hepatic Involvement - 76%-86% cases.
- Intraperitoneal spread - Ascites, omental nodules and peritoneal implants





# Spread Patterns





# Early Hepatic Plate Infiltration




Early Invasion of Hepatic Plate - Stage T3

47/M with a focal proliferative mass in the gall bladder fundus focally invading the hepatic plate in segment IVB [yellow arrows].





# Advanced Hepatic Plate Infiltration



54/F with a large proliferative mass replacing the entire gall bladder [which contains multiple calculi], invading the hepatic plate and porta hepatis with infiltration of the hepatoduodenal ligament and bile duct encasement.




# Hepatic Metastases



54/F with a large proliferative mass replacing the entire gall bladder with multiple hepatic metastases. Note the targetoid nature of these lesions demonstrating the “peripheral washout sign”.







Stage T3 - 60/M with focal eccentric mural thickening [restricted diffusivity], more pronounced along the peritoneal aspect, with transmural invasion and pericholecystic fat infiltration [orange arrow]. Note reserved fat plane with the liver.




# Peritoneal & Omental Disease






# Nodal Spread Pathways

- *Common route of dissemination.*
- *Cystic, pericholedochal and hilar nodes are the first key station of nodal involvement.*
- Ito et al. proposed three common pathways for lymphatic spread of gall bladder cancer:
  - 1) Cholecysto-retropancreatic pathway (*main pathway*).
  - 2) Cholecysto-celiac pathway (accessory pathway).
  - 3) Cholecysto-mesenteric pathway (accessory pathway).







### Cholecysto-retropancreatic pathway

62/F with a primary infiltrative GB mass [white asterix] invading the paraduodenal fat and 1st part of duodenum with an enlarged retropancreatic nodal mass [yellow arrow].

### Cholecysto-retropancreatic + Cholecystoceliac pathway

57/F with a large necrotic GB mass invading the liver, paraduodenal fat and 1st part of duodenum with an enlarged necrotic node ventral to the CHA [white asterix], non-necrotic node to the right of the celiac trunk [red asterix] and a large retropancreatic necrotic nodal mass [yellow arrow].






# PET/CT

- Primary staging
- Surveillance
- Recurrence Detection

Primary Staging  
GB mass with regional nodes



Primary Staging  
GB mass with regional and  
extensive supradiaphragmatic nodes



Elevated Ca 19-9 post surgery  
Note recurrent liver and lung lesions  
and supradiaphragmatic nodes





# Management of Ca Gall Bladder



National  
Comprehensive  
Cancer  
Network®

## NCCN Guidelines Version 2.2019 Gallbladder Cancer

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

### PRESENTATION WORKUP

Mass on  
imaging

- H&P
- Multiphasic abdominal/pelvic CT/MRI with IV contrast<sup>a</sup>
- Chest CT+/- contrast<sup>a</sup>
- Liver function tests (LFTs)
- Surgical consultation
- Assessment of hepatic reserve
- Consider CEA<sup>i</sup>
- Consider CA 19-9<sup>i</sup>
- Consider staging laparoscopy

Resectable<sup>b,c</sup>

Unresectable

Biopsy  
• MSI/MMR  
testing

### PRIMARY TREATMENT

Cholecystectomy<sup>b</sup>  
+ en bloc hepatic resection  
+ lymphadenectomy ± bile duct excision  
for malignant involvement

[See Adjuvant  
Treatment  
and  
Surveillance  
\(GALL-5\)](#)

Options:<sup>e</sup>

- Gemcitabine/cisplatin combination therapy<sup>f</sup> (category 1)
- Fluoropyrimidine-based or other gemcitabine-based chemotherapy regimen<sup>f</sup>
- EBRT with concurrent fluoropyrimidine<sup>g,h</sup>
- Radiation therapy<sup>h</sup>
- Clinical trial
- Best supportive care
- Pembrolizumab<sup>i</sup> (only for MSI-H/dMMR tumors)

# Mimics

Mimics	Pattern of presentation	Differentiating features
Adherent stone / sludge	Polypoidal mass	Mobile / immobile, hyperechoic, nonvascular balls
Xanthogranulomatous cholecystitis	Polypoidal mass	Hypodense band around the gallbladder on CT is the most specific finding
Adenomyomatosis	Focal wall thickening	Fluid-filled intramural diverticula (pearl necklace sign)
Metastatic melanoma	Focal wall thickening	Tendency for the serosal surface due to peritoneal implantation
Inflammatory thickening of GB wall	Diffuse wall thickening	Enhancement pattern – homogeneous. <i>c.f. Two-layer pattern</i> with strongly enhancing inner layer and weakly enhancing outer layer or <i>one-layer pattern with heterogeneous enhancement</i> s/o malignancy.
Primary lymphoma [extremely rare]	Diffuse wall thickening	Submucosal homogenous wall thickening



# Summary

- Ca GB is one the most common malignant neoplasm of the biliary tract with poor prognosis because it is usually detected at an advanced stage, with stage-adjusted therapy being cornerstone for improving survival.
- Only potentially curative therapy for Ca GB is surgical resection.
- Abdominal radiologists should understand key imaging features of gall bladder polyps and cancers, which would guide the clinician in appropriate patient management.